Tenofovir Disoproxil Fumarate and Entecavir in Patients with Chronic Hepatitis B: Efficacy and Safety Comparison Kronik Hepatit B Hastalarında Tenofovir Disoproksil Fumarat ve Entecavir: Etkinlik ve Güvenlik Karşılaştırması
Viral Hepatitis Journal, cilt.32, sa.1, ss.8-13, 2026 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.4274/vhd.galenos.2026.2025-12-3
- Dergi Adı: Viral Hepatitis Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.8-13
- Anahtar Kelimeler: Chronic hepatitis B, nucleos(t)ide analogues, entecavir, tenofovir disoproxil fumarate, virological response
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: Two potent nucleoside analogues frequently used to treat chronic hepatitis B (CHB) are entecavir (ETV) and tenofovir disoproxil fumarate (TDF). The purpose of this study was to examine the virological and biochemical therapeutic responses to TDF and ETV in CHB patients and to assess their effects on renal function. Materials and Methods: This was a single-center retrospective study. The study comprised patients diagnosed with CHB who had been treated with TDF or ETV for at least a year. Results: A total of treatment-naive 269 patients were analyzed, of whom 29% were hepatitis B e antigen positive. Among the patients, 26% (n=70/269) received ETV, whereas 74% (n=199/269) received TDF treatment. Patients receiving TDF were younger than those treated with ETV. The TDF group had significantly higher baseline hepatitis B virus DNA levels (log10 IU/mL) than the ETV group. Complete virological response was achieved in 232 (86.2%) of patients. Antiviral efficacy was comparable between treatments; however, a greater decline in estimated glomerular filtration rate was observed among patients receiving TDF. Conclusion: This study showed that TDF and ETV had comparable antiviral effectiveness. These findings provide updated real-world evidence supporting individualized selection of first-line antiviral therapy based on patients’ renal profiles.